Clearside Q2 net loss $9.1M; Phase 2b ODYSSEY enrollment underway, topline Q3 2024

Clearside Biomedical, Inc.

2023-Q2 EPS reported -$0.30 revenue$1,022,000

Net loss $9.1M ($0.15/share) vs $7.8M ($0.13) prior year; cash $35.0M, operations funded into Q3 2024.
Phase 2b ODYSSEY trial for CLS-AX in wet AMD actively enrolling at ~30 U.S. sites; topline data expected Q3 2024.
Partner Arctic Vision's NDA accepted in Australia for Arcatus (suprachoroidal treatment of uveitic macular edema).
R&D expenses $4.9M (down from $5.4M); license revenue $1.0M (up from $0.4M).
Board Chair changed to Clay B. Thorp; Scientific Advisory Board expanded with three new members.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Clearside Biomedical, Inc. reported the second quarter ended June 30, 2023 results: revenue $1.0 million.

Period: the second quarter ended June 30, 2023
Revenue: $1.0 million
Result: reported results

Exact text from the filing

input on the Company’s research and development programs. Second Quarter 2023 Financial Results • License Revenue: License and other revenue for the second quarter of 2023 was $1.0 million, compared to $0.4 million for the second quarter of 2022. • Cost of Goods Sold: Cost of Goods Sold for the second quarter of 2023 was $0.2 million, compared to $0 for the second

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-042410

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.